Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429650 | 0.79 | PKM (0.41) | ALDH1A1PKMATMHSD17B10 | |
| SCHEMBL15706622 | 0.77 | HSD17B10 (0.69) | MEN1KMT2AALDH1A1PKMATM | |
| SCHEMBL20223345 | 0.76 | PKM (0.50) | RECQLMEN1KMT2APKMATM | |
| SCHEMBL24018479 | 0.75 | MEN1 (0.44) | RECQLMEN1KMT2AALDH1A1PKM | |
| SCHEMBL17686526 | 0.75 | ALDH1A1 (0.47) | RECQLMEN1KMT2AALDH1A1PKM | |
| SCHEMBL3742035 | 0.75 | MEN1 (0.47) | RECQLMEN1KMT2APKMATM | |
| SCHEMBL6943164 | 0.72 | PKM (0.42) | RECQLMEN1KMT2APKMATM | |
| SCHEMBL20223423 | 0.71 | RECQL (0.39) | RECQLMEN1KMT2AALDH1A1PKM | |
| SCHEMBL24666635 | 0.71 | MEN1 (0.41) | RECQLMEN1KMT2AALDH1A1PKM | |
| SCHEMBL7080537 | 0.71 | MEN1 (0.41) | RECQLMEN1KMT2AALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| CN-116490499-A | Modulators of MYC family protooncogene proteins | 纳罗医疗公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4204411-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | Nalo Therapeutics (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-111051304-B | Imidazo [4,5-c ] quinoline derivatives as LRRK2 inhibitors | 辉瑞大药厂 | 2022-12-27 | — | — | CN | disclosed |
| WO-2022046861-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-3548478-B1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3137470-B1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | NOVARTIS AG (CH) | 2021-04-07 | — | — | EP | disclosed |
| US-8383643-B2 | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase | MERCK CANADA INC. (CA) | 2013-02-26 | — | — | US | disclosed |
| US-20120122912-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| US-20120010186-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2012-01-12 | — | — | US | disclosed |
| US-20110312952-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2011-12-08 | — | — | US | disclosed |
| US-20110152295-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2011-06-23 | — | — | US | disclosed |
| US-20100249192-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. | 2010-09-30 | — | — | US | disclosed |
| WO-2010108268-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-09-30 | — | — | WO | disclosed |
| US-20100120784-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-05-13 | — | — | US | disclosed |
| WO-2009073973-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249192-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | RECQL 2279/4885MEN1 4643/4885KMT2A 3333/4885 |
| US-20100120784-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, ACSL6 | RECQL 2437/4885MEN1 4756/4885KMT2A 2037/4885 |
| US-20110312952-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | RECQL 2399/4885MEN1 4145/4885KMT2A 4207/4885 |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | RECQL 2767/4885MEN1 1149/4885KMT2A 1611/4885 |
| US-20120010186-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, FASN | RECQL 2260/4885MEN1 4258/4885KMT2A 3367/4885 |
| US-20120122912-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | RECQL 2399/4885MEN1 4145/4885KMT2A 4207/4885 |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | RECQL 582/4885MEN1 4690/4885KMT2A 2064/4885 |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, COASY | RECQL 2871/4885MEN1 4582/4885KMT2A 3000/4885 |
| US-20110152295-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | RECQL 2147/4885MEN1 4525/4885KMT2A 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.